---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-25-000015"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T22:10:27.522058+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Haemonetics appoints Frank Chan as EVP COO, promotes Roy Galvin to CCO

## Summary
- Frank Chan appointed EVP COO effective April 7, 2025; oversees R&D, regulatory, global manufacturing & supply chain.
- Roy Galvin promoted to EVP, Chief Commercial Officer effective immediately; adds Global Hospital business to his remit.
- Chan's compensation: $550k base salary, 80% target bonus, $1.6M long-term equity award, plus $350k sign-on bonus.
- Chan most recently President of Medtronic's Acute Care & Monitoring business; 25+ years experience.
- Stewart Strong continues as President, Global Hospital through April 1, then advisor to CEO for transition.

## SEC filing metadata
- accession: 0000313143-25-000015
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/0000313143-25-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/hae-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-25-000015
- JSON: https://secwatch.observer/filing/0000313143-25-000015.json
- Plain text: https://secwatch.observer/filing/0000313143-25-000015.txt

## Key facts
- Executive change
  Frank W. Chan was appointed as Executive Vice President, Chief Operating Officer at HAEMONETICS CORP.
  - Action: appointed
  - Role: Executive Vice President, Chief Operating Officer
  source text: On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/313143/000031314325000015/0000313143-25-000015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.